RT Journal Article
T1 Selective Serotonin Reuptake Inhibitors as a risk factor for dental implant failure: A retrospective clinical study
A1 Rodríguez Pena, Karen
A1 Salgado Peralvo, Ángel Orión
A1 Kewalramani, Naresh
A1 Suárez Quintanilla, Juan Antonio
A1 Suárez Quintanilla, José María
AB Introduction: The trend in recent decades in Europe and the United States points to an exponential increase in the consumption of antidepressant drugs and, in particular, selective serotonin reuptake inhibitors (SSRIs). This retrospective study aims to investigate whether there is an association between SSRI intake and dental implant (DI) failure and, secondarily, the influence of other systemic and local factors.Material and Methods: This cohort retrospective study is in concordance with the STROBE guidelines for observational studies. One-hundred seventy patients received 573 DIs between 2014 and 2020.Results: The reported DI failure rate was 6.11%. Of these, 18.31% failed in patients treated with SSRIs while 4.38% failed in healthy patients (p<0.001). Specifically, the use of these drugs was associated with a 4.53 times higher rate of DI failure, and, in the multivariate analysis, 3.70 times higher adjusted risk was found. A lower survival rate at 90 months follow-up was also observed in these patients compared to those not taking these drugs (84.30% vs. 96%; p=0.00014).Conclusions: With the limitations of the present study, it can be affirmed that there is a relationship between the intake of SSRIs and DI failure, as well as a lower survival rate in these patients.
PB Elsevier
SN 1532-1940
YR 2022
FD 2022-10-01
LK https://hdl.handle.net/20.500.14352/72103
UL https://hdl.handle.net/20.500.14352/72103
LA eng
NO Rodríguez-Pena, K.; Salgado-Peralvo, Á.-O.; Kewalramani, N.; Suárez-Quintanilla, J.-A.; Suárez-Quintanilla, J.-M. Selective serotonin reuptake inhibitors as a risk factor for dental implant failure: a retrospective clinical study. British Journal of Oral and Maxillofacial Surgery 2022, 60(10), 1347–1352. doi:10.1016/j.bjoms.2022.09.009.
NO CRUE-CSIC (Acuerdos Transformativos 2022)
DS Docta Complutense
RD 5 abr 2025